VIRACTA

This year we are poised to deliver a steady cadence of anticipated catalysts, including updates from NAVAL-1 and complete dose escalation data from our advanced EBV+ solid tumor study. With these and other milestones ahead of us and a cash runway into late 2024, we believe Viracta is well-positioned to generate value for patients and shareholders over the coming months... We are a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Our lead product candidate is Nana-val, an all-oral combination therapy of our proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory EBV+ lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV+..

Also known as: Viracta Therapeutics, Viracta Therapeutics, Inc.

Primary location: Cardiff United States